Clinical trial approval for rare disease study

CBR, working with researchers from John Radcliffe Hospital Oxford and Evelina London Children’s Hospital, has successfully obtained approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) for a clinical trial of combination drug therapy for children with Opsoclonus/Myoclonus Syndrome, also known as Dancing Eye Syndrome, a rare disease that can affect movement and cognitive development.

A new study administrator has been appointed with funds obtained through CBR and the study is set to roll-out across the UK.

Leave a Comment


Email* (never published)